Twan foundation Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2019
NCT03962114
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Twan foundation

Active Ingredients

Drugs in Phase 2 Trials (1)

niacin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Ataxia Telangiectasia (Phase 2)

Cerebellar Ataxia (Phase 2)

Telangiectasis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1